LTI 291

Drug Profile

LTI 291

Alternative Names: LTI-291

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lysosomal Therapeutics
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Glucosylceramidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 06 Oct 2017 Phase-I clinical trials in Parkinson's disease (In adults, In the elderly, In volunteers) in Netherlands (PO) (NTR6705)
  • 09 Jan 2017 Allergan purchases an exclusive option right to acquire Lysosomal Therapeutics
  • 09 Jan 2017 Lysosomal Therapeutics plans a phase 1b trial for Parkinson's Disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top